Literature DB >> 17987403

Immunohistochemical detection of somatostatin receptor (SSTR) subtypes 2A and 5 in pituitary adenoma from acromegalic patients: good correlation with preoperative response to octreotide.

Mao Takei1, Masanori Suzuki, Hanako Kajiya, Yudo Ishii, Shigeyuki Tahara, Takashi Miyakoshi, Noboru Egashira, Susumu Takekoshi, Naoko Sanno, Akira Teramoto, Robert Yoshiyuki Osamura.   

Abstract

OBJECTIVE: The aim of this study was to determine the correlation between the expression of somatostatin receptors by immunohistochemistry and the percent suppression of GH levels in the octreotide suppression test. PATIENTS AND METHODS: Twenty-two patients with acromegaly who underwent an octreotide suppression test before surgery were studied. We performed immunohistochemistry for Somatostatin receptor 2A (SSTR2A) and Somatostatin receptor 5 (SSTR5) on the surgical specimens from all patients, which we scored according to the number of tumor cells staining positive at the surface membrane (3+: >50%, 2+: 25-50%, 1+: <25%). We sought correlations of percent suppression in the octreotide suppression test with these immunohistochemistry scores.
RESULTS: Somatostatin receptor 2A (SSTR2A) showed the highest frequency of score 3+ (13 of 22, 59.1%) by immunohistochemistry. Subtype 5 showed the highest frequency for score 2+ (9 of 22, 40.9%), and one (4.5%) was immunonegative. For subtype 2A, there was a significant correlation with percent decrease (P = 0.002 < 0.01). In contrast, there was no significant correlation for SSTR5.
CONCLUSION: Immunohistochemistry for SSTR2A in pathology specimens from acromegalic patients enabled selection of those experiencing clinical benefit from octreotide. Therefore, performing immunohistochemistry for detection of SSTR2A is recommended for all specimens obtained by surgery.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17987403     DOI: 10.1007/s12022-007-9004-0

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   4.056


  50 in total

1.  Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984.

Authors:  B A Bengtsson; S Edén; I Ernest; A Odén; B Sjögren
Journal:  Acta Med Scand       Date:  1988

2.  Poor responses to a test dose of subcutaneous octreotide predict the need for adjuvant therapy to achieve 'safe' growth hormone levels.

Authors:  J R Lindsay; E M McConnell; S J Hunter; D R McCance; B Sheridan; A B Atkinson
Journal:  Pituitary       Date:  2004       Impact factor: 4.107

3.  Structure and function of somatostatin receptors in growth hormone control.

Authors:  I Shimon; S Melmed
Journal:  J Endocrinol       Date:  1997-10       Impact factor: 4.286

4.  Limited predictive value of an acute test with subcutaneous octreotide for long-term IGF-I normalization with Sandostatin LAR in acromegaly.

Authors:  Wouter W de Herder; H Rob Taal; Piet Uitterlinden; Richard A Feelders; Joop A M J L Janssen; Aart-Jan van der Lely
Journal:  Eur J Endocrinol       Date:  2005-07       Impact factor: 6.664

5.  Intravenous octreotide test predicts the long term outcome of treatment with octreotide-long-acting repeatable in active acromegaly.

Authors:  Nienke R Biermasz; Alberto M Pereira; Jan W A Smit; Johannes A Romijn; Ferdinand Roelfsema
Journal:  Growth Horm IGF Res       Date:  2005-06       Impact factor: 2.372

6.  The somatostatin analog octreotide inhibits the secretion of growth hormone (GH)-releasing hormone, thyrotropin, and GH in man.

Authors:  A Masuda; T Shibasaki; Y S Kim; T Imaki; M Hotta; H Demura; N Ling; K Shizume
Journal:  J Clin Endocrinol Metab       Date:  1989-10       Impact factor: 5.958

7.  A comparison between octreotide-LAR and lanreotide-SR in the chronic treatment of acromegaly.

Authors:  R Cozzi; D Dallabonzana; R Attanasio; M Barausse; G Oppizzi
Journal:  Eur J Endocrinol       Date:  1999-09       Impact factor: 6.664

8.  Results of a European multicentre study with Sandostatin LAR in acromegalic patients. Sandostatin LAR Group.

Authors:  I Lancranjan; A B Atkinson
Journal:  Pituitary       Date:  1999       Impact factor: 4.107

9.  Outcome of transphenoidal surgery for acromegaly and its relationship to surgical experience.

Authors:  S Ahmed; M Elsheikh; I M Stratton; R C Page; C B Adams; J A Wass
Journal:  Clin Endocrinol (Oxf)       Date:  1999-05       Impact factor: 3.478

10.  Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy.

Authors:  U Plöckinger; M Reichel; U Fett; W Saeger; H J Quabbe
Journal:  J Clin Endocrinol Metab       Date:  1994-11       Impact factor: 5.958

View more
  14 in total

Review 1.  International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature.

Authors:  Thomas Günther; Giovanni Tulipano; Pascal Dournaud; Corinne Bousquet; Zsolt Csaba; Hans-Jürgen Kreienkamp; Amelie Lupp; Márta Korbonits; Justo P Castaño; Hans-Jürgen Wester; Michael Culler; Shlomo Melmed; Stefan Schulz
Journal:  Pharmacol Rev       Date:  2018-10       Impact factor: 25.468

2.  Expression of somatostatin receptor subtype 2 in growth hormone-secreting pituitary adenoma and the regulation of miR-185.

Authors:  X Fan; Z Mao; D He; C Liao; X Jiang; N Lei; B Hu; X Wang; Z Li; Y Lin; X Gou; Y Zhu; H Wang
Journal:  J Endocrinol Invest       Date:  2015-06-03       Impact factor: 4.256

3.  Low somatostatin receptor subtype 2, but not dopamine receptor subtype 2 expression predicts the lack of biochemical response of somatotropinomas to treatment with somatostatin analogs.

Authors:  L E A Wildemberg; L V Neto; D F Costa; L E Nasciuti; C M Takiya; L M Alves; A Rebora; F Minuto; D Ferone; M R Gadelha
Journal:  J Endocrinol Invest       Date:  2012-03-26       Impact factor: 4.256

4.  Clinical, biological, radiological, and pathological comparison of sparsely and densely granulated somatotroph adenomas: a single center experience from a cohort of 131 patients with acromegaly.

Authors:  Amy A Swanson; Dana Erickson; Diane Mary Donegan; Sarah M Jenkins; Jamie J Van Gompel; John L D Atkinson; Bradley J Erickson; Caterina Giannini
Journal:  Pituitary       Date:  2020-10-19       Impact factor: 4.107

Review 5.  Pituitary somatostatin receptor signaling.

Authors:  Anat Ben-Shlomo; Shlomo Melmed
Journal:  Trends Endocrinol Metab       Date:  2010-02-09       Impact factor: 12.015

6.  Correlation of monoclonal and polyclonal somatostatin receptor 5 antibodies in pancreatic neuroendocrine tumors.

Authors:  Daniel Kaemmerer; Amelie Lupp; Luisa Peter; Elke Fischer; Stefan Schulz; Günter Klöppel; Merten Hommann
Journal:  Int J Clin Exp Pathol       Date:  2012-11-20

7.  Validation of immunohistochemistry for somatostatin receptor subtype 2A in human somatotropinomas: comparison between quantitative real time RT-PCR and immunohistochemistry.

Authors:  L E A Wildemberg; L Vieira Neto; D F Costa; L E Nasciutti; C M Takiya; L M Alves; M R Gadelha
Journal:  J Endocrinol Invest       Date:  2011-09-06       Impact factor: 4.256

8.  Pathology, pathogenesis and therapy of growth hormone (GH)-producing pituitary adenomas: technical advances in histochemistry and their contribution.

Authors:  Robert Y Osamura; Noboru Egashira; Hanako Kajiya; Mao Takei; Maya Tobita; Takashi Miyakoshi; Chie Inomoto; Susumu Takekoshi; Akira Teramoto
Journal:  Acta Histochem Cytochem       Date:  2009-08-11       Impact factor: 1.938

Review 9.  Drug resistance in pituitary tumours: from cell membrane to intracellular signalling.

Authors:  Erika Peverelli; Donatella Treppiedi; Federica Mangili; Rosa Catalano; Anna Spada; Giovanna Mantovani
Journal:  Nat Rev Endocrinol       Date:  2021-06-30       Impact factor: 43.330

10.  Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience.

Authors:  Jessica Brzana; Chris G Yedinak; Sakir H Gultekin; Johnny B Delashaw; Maria Fleseriu
Journal:  Pituitary       Date:  2013-12       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.